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Background and purpose: To predict disability and cognition in multiple scle-
rosis (MS) after 6 and 12 years, using early clinical and imaging measures.
Methods: A total of 115 patients with MS were selected and followed up after
2 and 6 years, with 79 patients also being followed up after 12 years. Disabil-
ity was measured using the Expanded Disability Status Scale (EDSS); cogni-
tion was measured only at follow-up using neuropsychological testing.
Predictors of interest included EDSS score, baseline brain and lesion volumes
and their changes over 2 years, baseline age, clinical phenotype, sex and edu-
cational level.
Results: Higher 6-year EDSS score was predicted by early EDSS score and
whole-brain volume changes and baseline diagnosis of primary progressive MS
(adjusted R2 = 0.56). Predictors for 12-year EDSS score included larger EDSS
score changes and higher T1-hypointense lesion volumes (adjusted R2 = 0.38).
Year 6 cognition was predicted by primary progressive MS phenotype, lower
educational level, male sex and early whole-brain atrophy (adjusted
R2 = 0.26); year 12 predictors included male sex, lower educational level and
higher baseline T1-hypointense lesion volumes (adjusted R2 = 0.14).
Conclusions: Patients with early signs of neurodegeneration and a progressive
disease onset were more prone to develop both disability progression and cog-
nitive dysfunction. Male sex and lower educational level only aﬀected cogni-
tive dysfunction, which remains diﬃcult to predict and probably needs more
advanced imaging measures.
Introduction
Multiple sclerosis (MS) is a chronic inﬂammatory
demyelinating disease of the central nervous system
leading to neurodegeneration and chronic disability [1].
Predicting clinical progression with only inﬂammatory
magnetic resonance imaging (MRI) markers, such as
lesion load, remains diﬃcult [2,3]. Neurodegenerative
markers, such as atrophy, have stronger correlations
with disability and are present early in all disease phe-
notypes [4,5]. Atrophy is thought to be a promising pre-
dictor of disability progression on relatively short
follow-up (FU) periods [6–9], although results are less
consistent on longer-term FU and longitudinal studies
remain scarce [8,10,11].
In addition to physical disability, cognitive impair-
ment is also commonly present in MS [12] and cogni-
tive decline cannot be suﬃciently explained by white
matter lesion measures [13]. Cross-sectional studies
have shown a stronger relation between cognition and
atrophy measures [14–17] and longitudinal studies
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indicated that atrophy may be able to predict cogni-
tive impairment [18,19]. However, as with disability
studies, most studies included relatively short FU peri-
ods and rather small sample sizes [14–19]. Further-
more, it remains unclear whether important predictors
of physical disability, such as early imaging changes,
are also predictive of cognitive decline.
Consequently, additional longitudinal studies that can
conﬁrm the promising prognostic value of early atrophy
rates could help to identify patients with an especially
unfavourable prognosis for disability as well as cogni-
tion. Therefore, the aim of this study was to determine
the predictive value of early changes in brain, ventricular
and lesion volumes for physical disability and cognitive
function, after 6 and 12 years of MS.
Methods
Participants and clinical assessments
The study was approved by the institutional ethics
review board and all subjects gave written informed
consent prior to participation. Patients were selected
from the prospectively included Amsterdam MS early
inception cohort (n = 293) [20]. Patients with an MRI
scan at baseline and year 2 and clinical measurements
at year 6 were retrospectively selected and analysed
for the present study. Moreover, patients selected for
the present study also required a diagnosis of MS at
the latest at 6-year FU, using the 2005 McDonald cri-
teria [21]. Of all 293 patients in the early inception
cohort, our criteria resulted in the selection of 115
patients, with a mean age of 35.3 (SD 9.1) years of
whom 76 (66.1%) were female. A subset of patients
(n = 79) was also clinically assessed 12 years after
baseline [mean age 34.9 (SD 8.9) years, 54 (68.4%)
female]. Figure 1 shows an overview of all baseline
and FU measurements.
Previous MRI studies in the same cohort used dif-
ferent selection criteria and, for example, focused on
only disability as an outcome measure [10,20] with
shorter FU periods.
Disease-modifying treatment (DMT) strategies for
all patients remained at the discretion of the individual
treating physician. Educational level was measured
using a scale from 1 to 7, with 1 representing unﬁnished
primary school and 7 representing a university degree
or higher and subdivided into low (level 1–3), middle
(4 and 5) and high (6 and 7) levels of education [22].
Physical disability was measured using the Expanded
Disability Status Scale (EDSS) [23] by certiﬁed EDSS
raters at baseline, year 2, year 6 and year 12. Disability
Figure 1 Baseline and follow-up (FU) measurements. 9-HPT, 9-hole peg test; 25-FWT, timed 25-feet walk test; BL, baseline; EDSS,
Expanded Disability Status Scale. Timeline of the baseline and FU measurements that were obtained (baseline and year 2) and the
outcome measures (years 6 and 12) that were used. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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progression was used for descriptive purposes and
deﬁned as an increase in EDSS score of 1.5, 1.0 or 0.5
in the case of a baseline EDSS score of 0, 1.0–5.5 or ≥6,
respectively [24]. In addition, disability progression was
also described using the EDSS-plus, deﬁned as progres-
sion on EDSS score (using the aforementioned criteria)
or worsening of ≥20% on the 25-feet walk test or 9-hole
peg test at FU [25].
Cognition was assessed at 6- and 12-year FU (but
not at baseline or year 2), using a comprehensive set
of neuropsychological tests, which included a previ-
ously described expanded Brief Repeatable Battery of
Neuropsychological tests [26]. Cognitive domains
included executive functioning (concept shifting test),
verbal memory (selective reminding test), information
processing speed (symbol digit modalities test), verbal
ﬂuency (word list generation), visuospatial memory
(spatial recall test), working memory (memory com-
parison test) and attention (Stroop colour and word
test). As previously published [26], the results of the
diﬀerent tests at years 6 and 12 were corrected for
normal eﬀects of age, sex and education. In addition,
all cognitive data were corrected for normal changes
in cognition over time, which were quantiﬁed using
longitudinal data of 60 matched healthy controls,
measured at the time of 6- and 12-year FU. The Z-
scores of the diﬀerent cognitive domains were aver-
aged to derive a summary statistic of average cogni-
tion that was used for the statistical analyses. For
descriptive purposes, patients were classiﬁed as mildly
cognitively impaired when two of the domains had a
Z-score <1.5 SD compared with healthy controls and
as cognitively impaired when Z-scores on at least two
domains were ≥2 SD below the Z-scores of the
healthy controls, based on previous work on the same
cohort [26]. Otherwise, patients were classiﬁed as cog-
nitively preserved.
Magnetic resonance imaging
All patients underwent a brain MRI scan on a 1.0-T
magnetic resonance system at baseline and year 2
(Magnetom Impact Expert, Siemens AG, Erlingen,
Germany) between December 2000 and September
2007, using a standard MS scan protocol including
axial two-dimensional dual-echo proton density (PD)/
T2 spin echo images for T2-lesion volumes (repetition
time, 2700 ms; echo time, 45/90 ms; ﬂip angle, 90)
and axial two-dimensional T1-weighted spin echo
images (repetition time, 700 ms; echo time, 15 ms)
(both with 5-mm axial slices with a 0.5-mm gap, in-
plane resolution 1 9 1 mm2). Pseudo-T1 images (see
below) were created using the PD/T2 images and used
for atrophy measurements, in order to cancel out the
eﬀects of contrast administration, as pre-gadolinium
two-dimensional-T1-weighted sequences were often
lacking.
Magnetic resonance imaging processing
The T2-hyperintense and T1-hypointense lesion vol-
umes were identiﬁed by experienced readers (M.M.S.
and V.P.) with over 10 years of experience and out-
lined using a local thresholding technique, as
described previously [20]. T1-hypointense lesions were
classiﬁed as ‘black holes’ when their intensity was
equal to or lower than cortical grey matter. At base-
line and year 2, the PD/T2-weighted images were used
to create pseudo-T1 images for longitudinal atrophy
analyses [27,28]. The annualized percentage brain vol-
ume change (PBVC) and annualized percentage ven-
tricular volume change (PVVC) were calculated
between baseline and year 2 using SIENA [29] and
VIENA [30] (FSL 4.1, http://www.fmrib.ox.ac.uk/fsl)
on the pseudo-T1 images, after lesion ﬁlling. In short,
SIENA performs halfway registration between the
images from the two time points and calculates the
PBVC from the mean brain edge displacement
between the two scans. For PVVC, only brain/non-
brain edge points on the ventricular edges were
selected and their mean edge displacement was calcu-
lated. PBVC and PVVC were divided by the time
interval between the visits to obtain annualized
measures.
Statistical analyses
Normality of the data was checked by visual inspec-
tion of the histograms together with Kolmogorov–
Smirnov testing. T1- and T2-lesion volumes were
log-transformed. Multiple linear regression models
were used to predict physical disability (EDSS score)
and average cognitive performance (average Z-score)
at 6- and 12-year FU. A backward selection proce-
dure with a removal P = 0.10 was used; all reported
b values were standardized b coeﬃcients. Predictors
of interest were baseline age, highest level of educa-
tion attained, disease phenotype, EDSS score, T1-
and T2-lesion volumes and sex, as well as early
changes (i.e. between baseline and year 2) in EDSS
score, lesion volumes and annualized brain volume
changes (PBVC and PVVC). In order to reduce the
number of variables, baseline prognostic variables
were only selected for multiple linear regression if
univariate linear regression P < 0.10. Regression
analysis for disability and cognition at year 6 was
also performed including only the patients with 12-
year FU (n = 79).
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Baseline characteristics of patients with and without
12-year FU were compared using an independent-
samples t-test, chi-squared test or Mann–Whitney
U-test as appropriate. All statistical analyses were per-
formed in SPSS 22.0 (IBM, SPSS, Chicago, IL, USA)
(level of signiﬁcance was set at P = 0.05).
Results
A total of 115 patients of the Amsterdam MS cohort
were included. Patient characteristics at baseline,
6 years (n = 115) and 12 years (n = 79) are summa-
rized in Table 1.
At baseline, 36 patients (31.3%) were diagnosed
with a clinically isolated syndrome, 68 (59.1%) with
relapsing-remitting MS and 11 (9.6%) with primary
progressive MS (PPMS) using the 2005 McDonald
criteria [21]. At baseline, median disease duration
based on the ﬁrst symptom(s) was 0.92 [interquartile
range (IQR), 0.61–1.62] years and the median EDSS
score was 2.0 (IQR, 1.5–3.0). All baseline lesion vol-
umes are also shown in Table 1. Patients with PPMS
Table 1 Patient characteristics
All patients with
6 years FU
All patients
with 12 years FU
Clinical data
No. of patients 115 79
Disease type BL
CIS 36/115 (31.3%) 27/79 (34.2%)
RRMS 68/115 (59.1%) 50/79 (63.3%)
PPMS 11/115 (9.6%) 2/79 (2.5%)
Sex (female) 76/115 (66.1%) 54/79 (68.4%)
Age at BL (years) 35.3 (9.1) 34.9 (8.9)
Disease duration BL (years) 0.92 (0.61–1.62) 0.84 (0.61–1.60)
Level of education (range 1–7) 5 (4–6) 5 (4–6)
FU length (years) 5.9 (5.3–6.5) 11.8 (10.7–12.8)
Patients on DMT during FU 64/115 (55.7%) 50/79 (63.3%)
Disability
EDSS score BL 2.0 (1.5–3.0) 2.0 (1.5–3.0)
EDSS score at year 6 2.5 (2.0–3.5) 2.0 (1.5–3.0)
EDSS score at year 12 – 3.0 (2.0–4.0)
EDSS score diﬀerence 0–2 years 0.0 (0.5 to 0.5) 0.0 (0.5 to 1.0)
EDSS score progression at year 6 40/115 (34.8%) 24/79 (30.4%)
EDSS-plus score progression at year 6 54/112 (48.2%) 33/70 (42.3%)
EDSS score progression at year 12 – 40/79 (50.6%)
EDSS-plus score progression at year 12 – 46/70 (65.7%)
Cognition
SDMT at year 6 54 (49–62) 55 (49–62)
SDMT at year 12 – 53 (45–62)
Average cognition at year 6 (Z-score) 0.76 (0.94) 0.66 (0.73)
Average cognition at year 12 (Z-score) – 0.84 (0.77)
MCI at year 6 21/115 (18.3%) 11/79 (13.9%)
CI at year 6 28/115 (24.3%) 18/79 (22.8%)
MCI at year 12 – 14/79 (17.7%)
CI at year 12 – 23/79 (29.1%)
MRI measures
PBVC (%/year) 0.54 (0.55) 0.53 (0.57)
PVVC (%/year) 2.58 (3.86) 2.72 (4.31)
T1-hypointense lesion volume BL (mL) 0.21 (0.32) 0.22 (0.34)
T1-Gd+ lesion volumes BL (mL) 0.13 ( 0.51) 0.13 (0.23)
T2-hyperintense lesion volume BL (mL) 2.51 (2.74) 2.61 (3.06)
T1-hypointense lesion volume change 0–2 years (mL) 0.04 (0.22) 0.03 (0.22)
T1-Gd+ lesion volumes at year 2 (mL) 0.02 (0.05) 0.07 (0.15)
T2-hyperintense lesion volume change 0–2 years (mL) 0.18 (0.97) 0.19 (1.08)
Patient characteristics of the 115 patients followed until 6 years after baseline and the 79 patients who were also seen 12 years after BL are
given. Demographic, clinical and imaging information of both BL and FU are included. Data are given as mean  SD, median (IQR) and
n (%). BL, baseline; CI, cognitively impaired; CIS, clinically isolated syndrome; DMT, disease-modifying treatment; EDSS, Expanded
Disability Status Scale; FU, follow-up; Gd+, gadolinium enhancing; IQR, interquartile range; MCI, mildly cognitively impaired; MRI, mag-
netic resonance imaging; PBVC, percentage brain volume change; PPMS, primary progressive multiple sclerosis; PVVC, percentage ventricular
volume change; RRMS, relapsing-remitting multiple sclerosis; SDMT, symbol digit modalities test.
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
4 I. DEKKER ET AL.
had a median EDSS score of 3.5 (IQR, 2.5–3.5) at
baseline.
After 2 years of FU, median EDSS score remained
2.0 (IQR, 1.5–3.0), leading to an EDSS score change
between baseline and year 2 of 0.0 (IQR, 0.5 to 0.5).
Patients with PPMS had a median EDSS score of 4.0
(IQR, 4.0–5.0), which was a median of 0.5 (IQR, 0–
1.5) change in EDSS score compared with baseline.
Lesion and atrophy measurements are shown in
Table 1.
After 6 years, 96 patients (83.5%) had relapsing-
remitting MS, 8 patients (7.0%) converted to sec-
ondary progressive MS and 11 (9.6%) had PPMS.
Disability was still minimal with a median EDSS
score of 2.5 (IQR, 2.0–3.5). About one-third of the
patients showed EDSS score progression compared
with baseline (40/115 patients, 34.8%) and about half
of the patients showed EDSS-plus score progression
(54/112 patients, 48.2%). Average cognitive perfor-
mance at year 6 was Z = 0.76 (SD 0.94) below con-
trols; 49/115 patients (42.6%) were classiﬁed as either
mildly cognitively impaired (18.3%) or cognitively
impaired (24.3%). A total of 54 patients (47.0%) used
DMT at some point during the 6 years of FU.
Of the 79 patients who were evaluated after 12 years,
68 patients (86.1%) had relapsing-remitting MS, 9
(11.4%) had secondary progressive MS (of whom ﬁve
converted after the 6-year visit) and two (2.5%) had
PPMS. The median EDSS score at year 12 was 3.0
(IQR, 2.0–4.0), with EDSS score progression in 40/79
of the patients (50.6%) and EDSS-plus score progres-
sion in 46/70 patients (65.7%). The average cognitive
Z-score was 0.84 (SD 0.77) and 37/79 (46.8%)
patients were classiﬁed as either mildly cognitively
impaired (17.7%) or cognitively impaired (29.1%). A
total of 42 patients (53.2%) used DMT at some point
during the 12 years of FU. The subset of patients with
12-year FU showed signiﬁcantly lower EDSS scores at
baseline (P = 0.014), year 2 (P = 0.008) and year 6
(P = 0.001) than those who dropped out of the study,
but not on the EDSS score change between baseline
and year 2 (P = 0.280). Furthermore, a signiﬁcantly
lower number of patients with 12 years of FU had a
baseline diagnosis of PPMS (only 2/11 patients with
PPMS were followed for 12 years, P < 0.001). Results
of the subgroup followed over 12 years are presented
separately in Table 1.
Prediction of physical disability
The univariate models for disability are shown in
Table 2 and Fig. 2. Variables with P < 0.10 were
included for multivariate analyses as summarized in
Table 3.
At year 6, the prediction model for disability
explained 55.9% of the variance and included a higher
change in EDSS score between baseline and year 2
(standardized b = 0.465, P < 0.001), a diagnosis of
PPMS at baseline (standardized b = 0.214, P = 0.004)
and early whole-brain atrophy rate (PBVC, standard-
ized b = 0.143, P = 0.026).
The prediction model for disability at year 12
explained 37.5% of the variability in disability by a
worsening in EDSS score between baseline and year 2
(standardized b = 0.443, P < 0.001) and higher T1-
hypointense lesion volumes at baseline (standardized
b = 0.245, P = 0.008). Both models were corrected for
baseline EDSS score and the 6-year model also for
the use of DMT during FU.
Prediction of cognition
Prediction models for cognition included predictors
selected by univariate analyses (see Table 2 and
Fig. 2). Baseline EDSS score and DMT were not pre-
dictive of cognition and were therefore not included in
the models. The multivariate analyses for cognition
(Table 4) showed that lower cognitive functioning
after 6 years was explained for 25.5% by a model
containing a lower educational level (middle versus
low: standardized b = 0.364, P = 0.004; high versus
low: standardized b = 0.503, P < 0.001), male sex (s-
tandardized b = 0.213, P = 0.013), a diagnosis of
PPMS at baseline (standardized b = 0.201,
P = 0.019) and early whole-brain atrophy rate (PBVC,
standardized b = 0.181, P = 0.039).
After 12 years, 14.1% of the variance in cognitive
functioning was explained by a model consisting of
male sex (standardized b = 0.256, P = 0.019), lower
educational levels (high versus low: standardized
b = 0.242, P = 0.026) and higher T1-hypointense
lesion volumes at baseline (standardized b = 0.220,
P = 0.041).
When including only the 79 patients seen for the
12-year FU, prediction models for 6-year disability
and cognition remained generally similar (adj.
R2 = 0.49 for disability, 0.20 for cognition), although
the models did not include PPMS and PBVC
anymore.
Discussion
In this longitudinal cohort of patients with MS, we
determined early predictors for both physical disabil-
ity and cognitive impairment at medium- and long-
term FU. The results suggest that a diagnosis of
PPMS at baseline as well as faster early decreases in
whole-brain volume (PBVC) predict both worse
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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physical disability and worse cognitive functioning
6 years after onset. However, predicting cognitive
dysfunction remained more diﬃcult with the set of
measures available for this study. Interestingly, T1-
hypointense lesion volumes only became signiﬁcant in
the long-term prediction model for physical disability
as well as cognition. Early increases in EDSS score
were predictive of physical disability only and a low
educational level and male sex seemed speciﬁc for cog-
nitive dysfunction.
Predictive value of early whole-brain atrophy
In our study, faster whole-brain atrophy rate (PBVC)
was a predictor for both disability as well as lower
cognitive functioning after 6 years, but not for year
12. This seems to be in contrast to previous data in
which whole-brain atrophy, T2-lesion volumes at year
1 and central atrophy (measured with PVVC) predict
disability progression over 10 years [10]. Interestingly,
correction for baseline EDSS score and the use of
DMT, as was also performed in this study, excluded
whole-brain atrophy from their model. This seems to
support another study on brain atrophy and disability
progression in patients with a longer disease duration,
which found a relation between atrophy and disability
at 5 years, but not at 10 years of FU [8]. A small 2-
year FU study also showed that both disability and
cognitive impairment were correlated to loss of brain
parenchyma [18]. A possible explanation for the rela-
tive lack of predictive power for atrophy at longer
periods may be the drop-out of the more severe clini-
cal cases after longer periods of time. This was also
seen in the regression models including only the
patients with a 12-year FU in our cohort, which
resulted in prediction models after 6 years no longer
including patients with PPMS and PBVC as signiﬁ-
cant predictors. Furthermore, the lack of predictive
power may also be caused by the need for more speci-
ﬁc regional atrophy markers of neurodegeneration
that require higher ﬁeld strengths.
Predictive value of early central atrophy and lesions
Ventricular enlargement (PVVC) was not included in
any of the prediction models and did not show direct
correlations with cognition or disability at either time
point, whereas previous work found early ventricular
enlargement related to cognitive functioning [14,15]
and also disability [7,10]. Ventricular volume changes
are thought to closely reﬂect thalamic volume changes
[31], a structure known to closely relate to both
Table 2 Univariate analyses of potential predictors
Univariate linear regression
Disability year 6 Disability year 12 Cognition year 6 Cognition year 12
Standardized
b P-value
Standardized
b
P-
value
Standardized
b P-value
Standardized
b
P-
value
Age at BL 0.296 0.001 0.325 0.003 0.072 0.445 0.136 0.232
Sex (male versus female) 0.056 0.552 0.021 0.854 0.268 0.004 0.244 0.030
Education: medium versus low 0.311 0.020 0.222 0.189 0.503 <0.001 0.295 0.071
Education: high versus low 0.265 0.045 0.199 0.238 0.543 <0.001 0.438 0.008
Disease duration at BL 0.039 0.679 0.038 0.737 0.070 0.456 0.064 0.573
RRMS at BL 0.122 0.194 0.092 0.419 0.152 0.106 0.096 0.402
PPMS at BL 0.450 <0.001 0.173 0.127 0.274 0.003 0.147 0.195
EDSS score at BL 0.491 <0.001 0.364 0.001 0.262 0.005 0.109 0.339
EDSS score diﬀerence (BL–2 years) 0.364 <0.001 0.332 0.003 0.025 0.794 0.001 0.990
DMT during FU 0.179 0.055 0.132 0.244 0.071 0.451 0.113 0.323
T1-hypointense lesions BL 0.016 0.869 0.281 0.012 0.070 0.456 0.263 0.019
T1-Gd+ lesions BL 0.006 0.951 0.146 0.201 0.075 0.425 0.042 0.710
T2-hyperintense lesions BL 0.028 0.609 0.086 0.576 0.117 0.211 0.198 0.339
T1-hypointense lesions; early
change
0.106 0.260 0.025 0.829 0.059 0.531 0.067 0.558
T1-Gd+ lesions 2 years 0.110 0.286 0.101 0.427 0.037 0.721 0.107 0.346
T2-hyperintense lesions; early
change
0.085 0.367 0.061 0.592 0.029 0.760 0.016 0.889
PBVC; early change 0.158 0.091 0.037 0.743 0.222 0.017 0.010 0.931
PVVC; early change 0.048 0.609 0.064 0.576 0.145 0.122 0.109 0.339
Univariate analyses of the potential variables. Variables with a P < 0.10 (bold) were selected for the prediction models shown in Table 3 (dis-
ability) and Table 4 (cognition). BL, baseline; DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; FU, follow-up;
Gd+, gadolinium enhancing; PBVC, percentage brain volume change; PPMS, primary progressive multiple sclerosis; PVVC, percentage ventri-
cular volume change; RRMS, relapsing-remitting multiple sclerosis.
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cognitive and physical disability. Similar to our ﬁnd-
ings, another study on brain atrophy did not ﬁnd
PVVC as a predictor for disability. In that study,
brain volumes were measured at baseline, 5-year FU
(81 patients) and 10-year FU (50 patients) using a 1.5-
T magnetic resonance system [8], which could indicate
the need for longitudinal imaging at higher ﬁeld
strengths.
Table 3 Prediction models for disability
Prediction model disability (EDSS score) at 6-year FU
Adjusted R2 = 0.559 Standardized b P-value
EDSS score (BL–2 years) 0.465 <0.001
PPMS at BL 0.214 0.004
Early whole-brain atrophy rate (PBVC) 0.143 0.026
Prediction model disability (EDSS score) at 12-year FU
Adjusted R2 = 0.375 Standardized b P-value
EDSS score (BL–2 years) 0.443 <0.001
T1-hypointense lesion volume at BL 0.245 0.008
Prediction models for physical disability 6 and 12 years after BL.
Both prediction models are corrected for baseline EDSS and the
model for year 6 was also corrected for disease-modifying treatment
use during FU. Standardized b and corresponding P-value are given
per included variable. BL, baseline; EDSS, Expanded Disability Sta-
tus Scale; FU, follow-up; PBVC, percentage brain volume change
per year; PPMS, primary progressive multiple sclerosis.
Table 4 Prediction models for cognitive decline
Prediction model cognition at 6-year FU
Adjusted R2 = 0.255 Standardized b P-value
High versus low level of education 0.503 <0.001
Middle versus low level of education 0.364 0.004
Male sex 0.213 0.013
PPMS at BL 0.201 0.019
Early whole-brain atrophy rate (PBVC) 0.181 0.039
Prediction model cognition at 12-year FU
Adjusted R2 = 0.141 Standardized b P-value
Male sex 0.256 0.019
High versus low level of education 0.242 0.026
T1-hypointense lesion volume at BL 0.220 0.041
Prediction models for cognitive decline 6 and 12 years after BL. Stan-
dardized b and corresponding P-value are given per included variable.
BL, baseline; FU, follow-up; PBVC, percentage brain volume change
per year; PPMS, primary progressive multiple sclerosis.
Figure 2 Univariate analyses of predictors for disability and cognition after 6 and 12 years of follow-up (FU). Visualization of univari-
ate analyses of potential predictors for disability (a) and cognition (b). Standardized b and 95% conﬁdence interval (CI) of all vari-
ables for the 6-year FU (squares) and 12-year FU (circles). BL, baseline; DMT disease-modifying treatment; EDSS, Expanded
Disability Status Scale; Gd+, gadolinium enhancing; PBVC, percentage brain volume change; PPMS, primary progressive multiple
sclerosis; PVVC, percentage ventricular volume change; RRMS, relapsing-remitting multiple sclerosis. [Colour ﬁgure can be viewed at
wileyonlinelibrary.com]
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Lesion volumes, especially T2-hyperintense lesion
volumes, have also been suggested as predictors in
previous longitudinal studies [8,10], showing relatively
stronger correlation for T1-hypointense lesion vol-
umes with disability than T2-hyperintense lesion vol-
umes [8], although atrophy seems to show stronger
correlations [7,8,11,19]. However, the results of our
long-term FU did show a predictive role for T1-
hypointense lesion volumes, but not PBVC, suggesting
that baseline T1-hypointense lesion volumes may be
valuable for long-term FU.
Predicting disability versus predicting cognition
Previous longitudinal studies in MS investigating both
cognition and disability are scarce. In our study, wors-
ened atrophy and T1-lesion volumes over the ﬁrst
2 years were predictive for both cognitive dysfunction
and disability, suggesting neurodegeneration as a gen-
eral marker of poorer prognosis. In addition, some
predictors were unique to disability and others to cog-
nition. A more severe increase in EDSS score over the
ﬁrst 2 years was only predictive for disability, suggest-
ing that further study of the underlying mechanism of
early increases in disability may provide important
future clues. Interestingly, preventing such an early
disability progression with an early start of treatment
[32] may not be especially relevant for cognition, as
the use of DMT in our study was not related to
cognition.
In contrast, a lower level of education, which is a
known marker of poorer cognitive reserve, was only
predictive of cognitive impairment [33]. This may indi-
cate that the concept of cognitive reserve may indeed
be rather speciﬁc for cognition, although more
advanced measures of reserve, such as brain reserve,
were not included in the present study. Interestingly, a
previous study did indicate cognitive reserve as being
protective for disability progression [34], which could
be due to a diﬀerent measurement of reserve. Another
unique predictor of cognitive decline was male sex,
which has previously been shown to be relevant for
subcortical atrophy and cognition in this cohort [35].
The use of DMT in our cohort was perhaps lower
than expected comparing with other cohorts; however,
the proportions are in line with DMT use described in
the Netherlands [36]. Although some predictors were
unique to cognition, the explained variance of cogni-
tive decline remained relatively low compared with
that of disability. This may indicate that we need
more advanced (functional) imaging measures to pre-
dict cognitive decline in particular.
The main limitation of our study lies within the low
ﬁeld strength, which was linked with the options
available at the time of baseline. Higher ﬁeld strengths
have been shown to increase accuracy, which is
promising for future research [37]. Additionally, we
focused on whole-brain atrophy and ventricular
enlargement, but spinal cord involvement is also
highly relevant for disability [20], which was not
included given the lack of relevance for cognition.
Unfortunately, not all patients were able to return at
12 years. Finally, cognitive performance at baseline
and more advanced baseline imaging would also be of
great interest in future studies.
Conclusions
In this study, disability as well as cognitive decline
were predicted by early signs of neurodegeneration
and a progressive disease onset. Male sex and lower
educational level only aﬀected cognitive dysfunction.
At both FU points, a more severe early change in
EDSS score was only predictive for disability, and a
lower educational level and male sex were only predic-
tive for cognitive impairment. Where around half of
the variance of disability progression could be
explained, the prediction of cognitive impair-
ment remains challenging and probably requires
more advanced imaging measures. Future research
with more advance imaging techniques would be
interesting.
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